Vaccines for Pseudomonas aeruginosa: a long and winding road

• Type of Material: Article
• Authors: Gregory P. Priebe, Harvard University; Joanna B. Goldberg, Emory University
• Language: English
• Date: 2014-04-01
• Publisher: Taylor & Francis: STM, Behavioural Science and Public Health Titles
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2014 Informa UK, Ltd.
• Final Published Version (URL): http://dx.doi.org/10.1586/14760584.2014.890053
• Title of Journal or Parent Work: Expert Review of Vaccines
• ISSN: 1476-0584
• Volume: 13
• Issue: 4
• Start Page: 507
• End Page: 519
• Grant/Funding Information: GPP is supported by grants from the NIH; the Cystic Fibrosis Foundation; and the William F. Milton Fund of Harvard Medical School.; JBG is supported by grants from the NIH and the Cystic Fibrosis Foundation.
• Keywords: Science & Technology; Th17; T-CELLS; NEUTROPHIL RECRUITMENT; OUTER-MEMBRANE PROTEIN; vaccine; COLONY-STIMULATING FACTOR; Pseudomonas aeruginosa; PULMONARY INFECTION; CYSTIC-FIBROSIS PATIENTS; flagella; Life Sciences & Biomedicine; HUMAN-IMMUNOGLOBULIN LOCI; Immunology; neutrophil; alginate; PSL EXOPOLYSACCHARIDE; MUCOID EXOPOLYSACCHARIDE; HUMAN MONOCLONAL-ANTIBODIES; lipopolysaccharide
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Immunology

Abstract

Despite the recognition of Pseudomonas aeruginosa as an opportunistic pathogen, no vaccine against this bacteria has come to market. This review describes the current state-of-the-art in vaccinology for this bacterium. This includes a discussion of those at risk for infection, the types of vaccines and the approaches for empirical and targeted antigen selection under development, as well as a perspective on where the field should go. In addition, the challenges in developing a vaccine for those individuals at risk are discussed.